

**Level 2, 66 Hunter Street
Sydney NSW 2000
Tel: (61-2) 9300 3344
Fax: (61-2) 9221 6333
E-mail: pnightingale@biotron.com.au
Website: www.biotron.com.au**

13 November 2018

The Manager Companies
ASX Limited
20 Bridge Street
SYDNEY NSW 2000

(2 pages by email)

Dear Madam,


Presentation of BIT225-009 HIV-1 Phase 2 Data

The Directors of Biotron Limited ('Biotron') are pleased to advise that an abstract entitled "BIT225-009: Significant Immunological Outcomes after 12 weeks of BIT225 and Antiretroviral Therapy in an HIV-1 Phase 2 Clinical Trial" has been accepted for presentation at the upcoming HIV DART and Emerging Viruses 2018 meeting to be held in Miami, Florida from 27 to 29 November 2018.

HIV DART and Emerging Viruses 2018 is a biannual meeting that aims to bridge the gap between the latest scientific developments and routine clinical practice in the context of HIV infection and emerging viruses.

The presentation will be released to the market at the time of the meeting.

Yours sincerely



Peter J. Nightingale
Company Secretary

pjn9695

About Biotron

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for HIV-1, and a promising preclinical program for HBV. In addition, Biotron has several earlier stage programs designing drugs that target a class of virus protein known as viroporins which have a key role in the virus life cycle of a very broad range of viruses, many of which have caused worldwide health issues such as Dengue, Ebola, Middle East Respiratory virus, Influenza and Zika viruses.

Enquiries

Dr Michelle Miller
Managing Director
Biotron Limited
+61-(0)412313329

Rudi Michelson
Monsoon Communications
+61-3 9620 3333